These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18566968)

  • 1. Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation.
    Weimer DL; Vining AR; Thomas RK
    Health Econ; 2009 Feb; 18(2):181-202. PubMed ID: 18566968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Approaches to Estimating Benefits of Regulations Affecting Addictive Goods.
    Cutler DM; Jessup AI; Kenkel DS; Starr MA
    Am J Prev Med; 2016 May; 50(5 Suppl 1):S20-S26. PubMed ID: 27102854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value to smokers of improved cessation products: evidence from a willingness-to-pay survey.
    Busch S; Falba T; Duchovny N; Jofre-Bonet M; O'Malley S; Sindelar J
    Nicotine Tob Res; 2004 Aug; 6(4):631-9. PubMed ID: 15370159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic man and the consumption of addictive goods: the case of two goods.
    Andersson L; Bask M; Melkersson M
    Subst Use Misuse; 2006; 41(4):453-66. PubMed ID: 16522558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using willingness to pay to measure family members' preferences in mental health.
    Mulvaney-Day NE
    J Ment Health Policy Econ; 2005 Jun; 8(2):71-81. PubMed ID: 15998979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subject variation more than values clarification explains the reliability of willingness to pay estimates.
    Shiell A; McIntosh K
    Health Econ; 2008 Feb; 17(2):287-92. PubMed ID: 17619235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of switching smoking cessation drugs to over-the-counter status.
    Keeler TE; Hu TW; Keith A; Manning R; Marciniak MD; Ong M; Sung HY
    Health Econ; 2002 Jul; 11(5):389-402. PubMed ID: 12112489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to pay for low-lung-cancer-risk cigarettes in Taiwan.
    Jan MS; Fu TT; Huang CL
    Health Econ; 2005 Jan; 14(1):55-67. PubMed ID: 15386675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The demand for health insurance coverage for tobacco dependence treatments: support for a benefit mandate and willingness to pay.
    Halpin HA; McMenamin SB; Shade SB
    Nicotine Tob Res; 2007 Dec; 9(12):1269-76. PubMed ID: 18058345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 'reference goods' in contingent valuation: should we help respondents to 'construct' their willingness to pay?
    Smith RD
    Health Econ; 2007 Dec; 16(12):1319-32. PubMed ID: 17328037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative approaches to obtain optimal bid values in contingent valuation studies and to model protest zeros. Estimating the determinants of individuals' willingness to pay for home care services in day case surgery.
    Dalmau-Matarrodona E
    Health Econ; 2001 Mar; 10(2):101-18. PubMed ID: 11252042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to pay for a QALY.
    Gyrd-Hansen D
    Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between reliability and size of willingness-to-pay values: a qualitative insight.
    Smith RD
    Health Econ; 2007 Feb; 16(2):211-6. PubMed ID: 16929470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demand analysis of tobacco consumption in Malaysia.
    Ross H; Al-Sadat NA
    Nicotine Tob Res; 2007 Nov; 9(11):1163-9. PubMed ID: 17978990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical implications of response acquiescence in discrete-choice contingent valuation.
    Yeung RY; Smith RD; Ho LM; Johnston JM; Leung GM
    Health Econ; 2006 Oct; 15(10):1077-89. PubMed ID: 16518835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealed preference valuation compared to contingent valuation: radon-induced lung cancer prevention.
    Kennedy CA
    Health Econ; 2002 Oct; 11(7):585-98. PubMed ID: 12369061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic value of informal care: a study of informal caregivers' and patients' willingness to pay and willingness to accept for informal care.
    van den Berg B; Bleichrodt H; Eeckhoudt L
    Health Econ; 2005 Apr; 14(4):363-76. PubMed ID: 15744739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What explains willingness to pay for smoking-cessation treatments - addiction level, quit-rate effectiveness or the opening bid?
    Olsen JA; Røgeberg OJ; Stavem K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):407-15. PubMed ID: 22938035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.
    Chen YT; Ying YH; Chang K; Hsieh YH
    Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26938547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.